Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Cardurion Pharmaceuticals is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Mendelsohn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cardurion Pharmaceuticals

Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion’s product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients.  Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733.  Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.

To learn more about Cardurion Pharmaceuticals, visit http://cardurion.com/

Contact:
Michael Mendelsohn, Chief Executive Officer
617-863-8088

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved